CG Oncology, Inc. (CGON)

CG Oncology's stock has experienced several notable events in the past six months. The stock price increased by 25.36% in the past month and nearly 79% over the last 12 months. In September 2025, the company presented data from its BOND-003 Cohort C and completed enrollment for its PIVOT-006 clinical trial ahead of schedule. In November 2025, the company initiated its rolling BLA submission for cretostimogene. Analyst sentiment has been positive, with Morgan Stanley and Truist Securities raising their price targets. CG Oncology's stock reached an all-time high of $57.4 USD on January 21, 2026. Director James Mulay sold 11,145 shares of common stock for $584,798 on January 9, 2026. The company filed an amendment to increase its stock offering to $550 million on January 13, 2026. Following its Q3 2025 and Q2 2025 earnings reports, the stock price increased by 8.61% and 2.05% the next day, respectively.

The demand for CG Oncology's products and services is directly linked to the incidence and prevalence of bladder cancer, particularly NMIBC, and the ongoing need for effective treatment options. Given that cancer treatment is a continuous medical need, there is no indication of seasonality in the demand for CG Oncology's products and services.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer patients. Their core business centers around cretostimogene, an oncolytic immunotherapy being evaluated in clinical trials for non-muscle invasive and muscle-invasive bladder cancer. The company's major product pipeline includes BOND-003, a Phase 3 trial for high-risk BCG-unresponsive NMIBC; CORE-001, a Phase 2 trial evaluating cretostimogene with pembrolizumab for high-risk BCG-unresponsive NMIBC; CORE-002, investigating cretostimogene with nivolumab for muscle invasive bladder cancer; PIVOT-006, a Phase 3 trial assessing cretostimogene as a monotherapy for intermediate-risk NMIBC; and CORE-008, a Phase 2 trial for high-risk NMIBC patients.

CG Oncology is headquartered in Irvine, California, United States. Its sales activities are primarily in biotechnology and concentrated in the United States, with no detailed information available regarding operations or significant market presence in other countries.

CG Oncology maintains a strong brand reputation within the investment and scientific communities. Analysts have a consensus "Strong Buy" rating for CGON, with a significant upside potential based on the average 12-month price target. Favorable feedback from Key Opinion Leaders regarding the durability and efficacy of cretostimogene, along with progress in clinical trials, has contributed to investor optimism. The company's focus on bladder-sparing immunotherapies addresses a substantial unmet medical need, further enhancing its reputation.

CG Oncology has a high level of institutional ownership at 99.58%, with 378 institutional owners and shareholders holding 84,688,011 shares. Major institutional shareholders include Vanguard Group Inc, Decheng Capital LLC, Wellington Management Group Llp, and BlackRock, Inc. Individual ownership accounts for 0.81% of the company's shares based on the 1000 largest holdings.